KR940013511A - 눈 또는 코에 사용하기 위한 항알레르기 조성물 - Google Patents

눈 또는 코에 사용하기 위한 항알레르기 조성물 Download PDF

Info

Publication number
KR940013511A
KR940013511A KR1019930029576A KR930029576A KR940013511A KR 940013511 A KR940013511 A KR 940013511A KR 1019930029576 A KR1019930029576 A KR 1019930029576A KR 930029576 A KR930029576 A KR 930029576A KR 940013511 A KR940013511 A KR 940013511A
Authority
KR
South Korea
Prior art keywords
composition according
cellulose
antiallergic
cyclodextrin
antiallergic composition
Prior art date
Application number
KR1019930029576A
Other languages
English (en)
Other versions
KR100276743B1 (ko
Inventor
요시후미 이께지리
다까히로 오가와
후미노리 도꾸모찌
소고 사메시마
모또꼬 기무라
Original Assignee
요시다 쇼오지
센쥬세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 요시다 쇼오지, 센쥬세이야꾸 가부시끼가이샤 filed Critical 요시다 쇼오지
Publication of KR940013511A publication Critical patent/KR940013511A/ko
Application granted granted Critical
Publication of KR100276743B1 publication Critical patent/KR100276743B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

활성성분으로서 세티리진 또는 그의 염을 함유함을 특징으로 하는, 눈 또는 코에 사용되는 항알레르기 조성물. 항알레르기 조성물은 시클로덱스트린 화합물 뿐만 아니라, 계면 활성제 및/또는 수용성 중합체를 추가로 함유할 수 있다.

Description

눈 또는 코에 사용하기 위한 항알레르기 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (13)

  1. 활성성분으로서 하기 구조식의 화합물 또는 그의 염을 함유함을 특징으로 하는, 눈 또는 코에 사용되는 항알레르기 조성물:
  2. 제1항에 있어서, 시클로덱스트린 화합물을 추가로 함유하는 항알레르기 조성물.
  3. 제2항에 있어서, 시클로덱스트린 화합물이 α-시클로덱스트린, β-시클로덱스트린, 및 γ-시클로덱스트린으로 구성된 군으로 부터 선택된 항알레르기 조성물.
  4. 제2항에 있어서, 계면활성제를 추가로 함유하는 항알레르기 조성물.
  5. 제2항 또는 4항에 있어서, 수용성 중합체를 추가로 함유하는 항알레르기 조성물.
  6. 제4항에 있어서, 계면활성제가 비이온계인 항알레르기 조성물.
  7. 제6항에 있어서, 비이온계 계면활성제가 폴리소르베이트 80 및 폴리옥시에틸렌 수소화 파마자유로 구성된 군으로 부터 선택된 항알레르기 조성물.
  8. 제5항에 있어서, 수용성 중합체가 셀룰로오스 유도체, 비닐 중합체 및 폴리올로 부터 선택된 항알레르기 조성물.
  9. 제8항에 있어서, 셀룰로오스 유도체가 알킬셀룰로오스 및 히드록시알킬셀룰로오스를 포함하는 항알레르기 조성물.
  10. 제9항에 있어서, 알킬셀룰로오스가 메틸셀룰로오스 및 카르복시메틸셀룰로오스를 포함하는 항알레르기 조성물.
  11. 제9항에 있어서, 히드록시알킬셀룰로오스가 히드록시프로필메틸셀룰로오스 및 히드록시에틸셀룰로오스를 포함하는 항알레르기 조성물.
  12. 제8항에 있어서, 비닐 중합체가 폴리비닐알콜 및 폴리비닐 피롤리돈을 포함하는 항알레르기 조성물.
  13. 제8항에 있어서, 폴리올이 마크로골 4000을 포함하는 항알레르기 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930029576A 1992-12-25 1993-12-24 눈 또는 코에 사용하기 위한 항알레르기 조성물 KR100276743B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP34603192 1992-12-25
JP92-346031 1992-12-25

Publications (2)

Publication Number Publication Date
KR940013511A true KR940013511A (ko) 1994-07-15
KR100276743B1 KR100276743B1 (ko) 2001-01-15

Family

ID=18380671

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930029576A KR100276743B1 (ko) 1992-12-25 1993-12-24 눈 또는 코에 사용하기 위한 항알레르기 조성물

Country Status (23)

Country Link
US (1) US5419898A (ko)
EP (1) EP0605203B1 (ko)
JP (1) JP3683595B2 (ko)
KR (1) KR100276743B1 (ko)
CN (1) CN1050514C (ko)
AT (1) ATE164068T1 (ko)
AU (1) AU666413B2 (ko)
BG (1) BG61101B1 (ko)
CA (1) CA2112014C (ko)
CZ (1) CZ283029B6 (ko)
DE (1) DE69317537T2 (ko)
DK (1) DK0605203T3 (ko)
ES (1) ES2115733T3 (ko)
FI (1) FI111805B (ko)
HU (2) HU218672B (ko)
LT (1) LT3344B (ko)
LV (1) LV10688B (ko)
NO (2) NO934630D0 (ko)
NZ (1) NZ250519A (ko)
PL (1) PL173347B1 (ko)
RU (1) RU2130774C1 (ko)
SK (1) SK279503B6 (ko)
TW (1) TW401300B (ko)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
EP0780127A1 (en) * 1995-12-19 1997-06-25 The Procter & Gamble Company A nasal spray containing a steroid and a antihistamine
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
AU714913B2 (en) * 1996-09-27 2000-01-13 Nastech Pharmaceutical Company, Inc. Intranasal formulations for promoting sleep and method of using the same
BE1011251A3 (fr) * 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
EP0919550A1 (en) * 1997-11-26 1999-06-02 Ucb, S.A. Pseudopolymorphic forms of 2-2-4-bis(4-fluorophenyl)methyl-1-piperazinyl-ethoxy acetic acid dihydrochloride
DE19814256A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Feste, schnellzerfallende Cetirizin-Formulierungen
IT1303671B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
US20030059440A1 (en) * 1998-09-01 2003-03-27 Tim Clarot Composition and method for moisturizing nasal tissue
WO2000012137A1 (en) 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
BR9804993A (pt) * 1998-11-10 2000-06-06 Panacea Biotec Ltd Composição antialérgica e antiinflamatória
JP2001125052A (ja) * 1999-10-25 2001-05-11 Lion Corp コンタクトレンズ装着液
US6258814B1 (en) * 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
EP1467715B1 (en) * 2002-01-15 2010-11-03 Ucb Farchim S.A. Formulations for oral administration of active compounds
JP4543274B2 (ja) * 2002-10-01 2010-09-15 大正製薬株式会社 点鼻剤組成物
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20050255154A1 (en) * 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
JP2008500288A (ja) * 2004-05-28 2008-01-10 イメイジノット ピーティーワイ エルティーディー 経口治療用化合物の供給系
JP2006008568A (ja) * 2004-06-24 2006-01-12 Cyclochem:Kk ＩｇＥ抗体抑制剤および食品
PE20060484A1 (es) * 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
US20080075784A1 (en) * 2004-07-22 2008-03-27 Pfizer Inc. Taste Making Formulation Comprising The Drug In A Dissolution-Retarded Form And/Or Cyclodextrin In A Dissolution-Enhanced Form
ES2393768T3 (es) 2005-05-26 2012-12-27 Neuron Systems, Inc Derivado de quinolina para el tratamiento de enfermedades retinianas
JPWO2006137433A1 (ja) * 2005-06-21 2009-01-22 わかもと製薬株式会社 レボカバスチンを可溶化させた水性薬剤
EP3449928A1 (en) * 2005-11-28 2019-03-06 Imaginot Pty Ltd. Oral therapeutic compound delivery system
AU2007225798B2 (en) * 2006-03-13 2012-09-06 R-Tech Ueno, Ltd. Aqueous composition
WO2008025560A1 (en) * 2006-09-01 2008-03-06 Pari Pharma Gmbh Methods for taste masking of nebulised compositions for nasal and pulmonary inhalation therapy
CN101284026B (zh) * 2007-04-12 2010-11-10 鲁南制药集团股份有限公司 一种用于治疗皮肤过敏性疾病的药物组合物
US9358242B2 (en) * 2007-08-30 2016-06-07 Prelief Inc. Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
PT2408453T (pt) * 2009-03-17 2022-04-05 Nicox Ophthalmics Inc Formulações oftálmicas de cetirizina e métodos de utilização
US8569273B2 (en) * 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
KR20120059545A (ko) * 2009-08-12 2012-06-08 루난 베터 파마슈티칼 씨오., 엘티디 세티리진염산염 약용액
EP2496593B1 (en) 2009-11-06 2015-08-12 Yale University Amphiphilic compositions and methods for preparing and using same
CA2852716C (en) 2011-11-29 2015-11-17 Jurox Pty Ltd Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
KR102435676B1 (ko) 2013-01-23 2022-08-24 알데이라 테라퓨틱스, 아이엔씨. 독성 알데히드 관련된 질병 및 치료
AU2016311158A1 (en) 2015-08-21 2018-04-05 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
EP3419633A4 (en) * 2016-02-28 2019-10-30 Aldeyra Therapeutics, Inc. TREATMENT OF ALLERGIC EYE DISEASES WITH CYCLODEXTRINS
EP3454858A4 (en) 2016-05-09 2020-01-15 Aldeyra Therapeutics, Inc. POLYTHERAPY OF DISORDERS AND INFLAMMATORY EYE DISEASES
JP6843896B2 (ja) * 2017-02-13 2021-03-17 日東メディック株式会社 水性点眼点鼻用組成物
JP2020511461A (ja) 2017-03-16 2020-04-16 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
AU2018348174A1 (en) 2017-10-10 2020-04-23 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
ES2878107T3 (es) * 2018-01-18 2021-11-18 Faes Farma Sa Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación
JP2021533154A (ja) 2018-08-06 2021-12-02 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
CN113056353B (zh) 2018-09-25 2022-11-01 奥尔德拉医疗公司 用于治疗干眼病的调配物
WO2020198064A1 (en) 2019-03-26 2020-10-01 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155805C (no) * 1981-02-06 1987-06-10 Ucb Sa Analogifremgangsmaate for fremstilling av terapeutisk virksomme 2-(4-(difenylmethyl)-1-piperazinyl)-eddiksyrer og deres amider og ikke-toksiske salter.
NZ224497A (en) * 1987-05-18 1990-04-26 Janssen Pharmaceutica Nv Pharmaceutical composition comprising flunarizine
US5188826A (en) * 1988-02-08 1993-02-23 Insite Vision Incorporated Topical ophthalmic suspensions
AU636685B2 (en) * 1989-12-18 1993-05-06 Alcon Laboratories, Inc. Compositions of antiallergics and antihistamines and methods for their use
US5192780A (en) * 1989-12-18 1993-03-09 Alcon Laboratories, Inc. Methods using antiallergics and antihistamines
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
JPH06311353A (ja) 1993-04-19 1994-11-04 Brother Ind Ltd カラー画像形成装置
JP2619828B2 (ja) 1996-06-17 1997-06-11 九州日立マクセル株式会社 電動式爪みがき機

Also Published As

Publication number Publication date
HU218672B (hu) 2000-10-28
FI935851A (fi) 1994-06-26
JPH06239748A (ja) 1994-08-30
FI111805B (fi) 2003-09-30
KR100276743B1 (ko) 2001-01-15
RU2130774C1 (ru) 1999-05-27
NO934630D0 (no) 1993-12-15
CA2112014C (en) 2004-11-02
EP0605203A2 (en) 1994-07-06
FI935851A0 (fi) 1993-12-23
LT3344B (en) 1995-07-25
PL301588A1 (en) 1994-06-27
NZ250519A (en) 1995-03-28
BG61101B1 (bg) 1996-11-29
LTIP1669A (en) 1994-10-25
TW401300B (en) 2000-08-11
NO934630L (no) 1994-06-27
HU211972A9 (en) 1996-01-29
DE69317537D1 (de) 1998-04-23
JP3683595B2 (ja) 2005-08-17
HU9303746D0 (en) 1994-04-28
HUT69385A (en) 1995-09-28
DK0605203T3 (da) 1998-12-07
BG98327A (bg) 1994-08-30
CZ283029B6 (cs) 1997-12-17
AU666413B2 (en) 1996-02-08
PL173347B1 (pl) 1998-02-27
SK147493A3 (en) 1994-07-06
ATE164068T1 (de) 1998-04-15
SK279503B6 (sk) 1998-12-02
LV10688B (en) 1995-10-20
CA2112014A1 (en) 1994-06-26
EP0605203B1 (en) 1998-03-18
DE69317537T2 (de) 1998-07-09
LV10688A (lv) 1995-06-20
US5419898A (en) 1995-05-30
ES2115733T3 (es) 1998-07-01
AU5259793A (en) 1994-07-07
CN1094614A (zh) 1994-11-09
NO304176B1 (no) 1998-11-09
CZ283693A3 (en) 1994-07-13
EP0605203A3 (en) 1994-11-02
CN1050514C (zh) 2000-03-22

Similar Documents

Publication Publication Date Title
KR940013511A (ko) 눈 또는 코에 사용하기 위한 항알레르기 조성물
KR950701515A (ko) 눈의 조성물(ophthalmic compositions)
FI964624A (fi) Menetelmä duokarmysiinijohdannaisten stabiloimiseksi
KR920003971A (ko) 점안액 조성물
ATE272063T1 (de) Rapamycin-derivate und ihre verwendung, insbesondere als immunosuppressoren
DE69333850D1 (de) Anwendung von boral-polyol-komplexen für ophthalmische arzneizusammensetzungen
DE69323937D1 (de) Cyclodextrin-Komplexation
KR960700039A (ko) β-시클로덱스트린 유도체 및 탄산 탈수효소 저해제로 이루어진 안과용 국소 투여 조성물(Topical Compositions for the Eye Comprising a β-cyclodextrin Derivative and a Carbonic Anhydrase Inhibitor)
CA2161774A1 (en) Synthetic viscoelastic material for ophthalmic applications
EP0862414A1 (en) Ophthalmic compositions containing cyclodextrins and quaternary ammonium compounds
NO950243L (no) Nye nimesulidsalt-cyklodekstrin-inklusjonskomplekser
DE69420832T2 (de) Die Verwendung von Carbostyrilderivaten zur Herstellung eines Arzneimittels zur Hemmung der Produktion von Interleukin-8
ATE273704T1 (de) Ophthalmische histamin-enthaltende zusammensetzungen und deren verwendung
KR950013496A (ko) 구강용 겔조성물
PT1157688E (pt) Formulacoes oftalmicas aquosas antibacterianas contendo ofloxacina e quitosano
TH14981A (th) สารผสมสำหรับต่อต้านภูมิแพ้สำหรับการใช้เกี่ยวกับตาหรือจมูก
FI955142A0 (fi) Bentso(f)kinoksaliinidionijohdannaisia, niiden valmistus ja käyttö lääkkeinä

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20080922

Year of fee payment: 9

LAPS Lapse due to unpaid annual fee